Epcoritamab (GEN3013)
Sponsors
Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon), AbbVie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG, Universitaet Muenster, Fundacion Geltamo
Conditions
B-cell Non-Hodgkin's lymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL)Follicular LymphomaFollicular lymphoma (FL) grade 3BHigh-grade B-cell lymphoma (HGBL)Relapse/Refractory Large B Cell Lymphoma
Phase 1
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
Active, not recruitingCTIS2023-504795-20-00
Start: 2022-05-20Target: 6Updated: 2025-06-09
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma.
AETHER study (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL)
RecruitingCTIS2022-500305-40-00
Start: 2024-04-10Target: 112Updated: 2025-06-30
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma
RecruitingCTIS2023-505347-38-00
Start: 2022-06-13Target: 59Updated: 2025-11-21
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
Not yet recruitingCTIS2025-522295-91-00
Target: 14Updated: 2026-03-11
Phase 2
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
WithdrawnCTIS2023-509861-19-00
Target: 104Updated: 2025-04-24
Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of Eptoritamab in Patients with Relapse/Refractory Large B Cell Lymphoma
RecruitingCTIS2024-514440-86-00
Start: 2025-08-04Target: 80Updated: 2025-10-06
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
RecruitingCTIS2023-509861-19-01
Start: 2025-09-30Target: 104Updated: 2025-12-29
Phase 3
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
RecruitingCTIS2023-505277-32-00
Start: 2023-01-26Target: 435Updated: 2025-12-11
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)
Active, not recruitingCTIS2023-505628-67-00
Start: 2022-10-28Target: 280Updated: 2025-12-19
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Active, not recruitingCTIS2023-506906-38-00
Start: 2024-05-23Target: 357Updated: 2026-01-20
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingCTIS2024-510965-41-00
Start: 2024-09-03Target: 116Updated: 2025-12-15